No abstract available
Keywords:
cellular FLIP; hidradenitis; leukemia; omacetaxine; rash.
Publication types
-
Clinical Trial, Phase I
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Agents, Phytogenic / administration & dosage
-
Antineoplastic Agents, Phytogenic / adverse effects
-
Antineoplastic Agents, Phytogenic / pharmacology*
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Apoptosis
-
CASP8 and FADD-Like Apoptosis Regulating Protein / analysis*
-
CASP8 and FADD-Like Apoptosis Regulating Protein / biosynthesis
-
CASP8 and FADD-Like Apoptosis Regulating Protein / genetics
-
Cyclophosphamide / administration & dosage
-
Cytarabine / administration & dosage
-
Daunorubicin / administration & dosage
-
Down-Regulation
-
Drug Eruptions / etiology
-
Hidradenitis / chemically induced*
-
Hidradenitis / pathology
-
Homoharringtonine / administration & dosage
-
Homoharringtonine / adverse effects
-
Homoharringtonine / pharmacology*
-
Humans
-
Incidence
-
Leukemia, Myeloid, Acute / drug therapy*
-
Mercaptopurine / administration & dosage
-
Myeloid Cell Leukemia Sequence 1 Protein / analysis
-
Neoplasm Proteins / analysis*
-
Neoplasm Proteins / biosynthesis
-
Neoplasm Proteins / genetics
-
Neutrophils
-
Protein Kinase Inhibitors / administration & dosage
-
Protein Kinase Inhibitors / adverse effects
-
Protein Kinase Inhibitors / pharmacology*
-
Sweat Glands / chemistry
-
Sweat Glands / drug effects
-
Sweat Glands / pathology
Substances
-
Antineoplastic Agents, Phytogenic
-
CASP8 and FADD-Like Apoptosis Regulating Protein
-
MCL1 protein, human
-
Myeloid Cell Leukemia Sequence 1 Protein
-
Neoplasm Proteins
-
Protein Kinase Inhibitors
-
Cytarabine
-
Homoharringtonine
-
Cyclophosphamide
-
Mercaptopurine
-
Daunorubicin